Price Movement and Market Context
On 6 Mar 2026, Rossari Biotech’s share price declined by 1.50%, underperforming the Sensex which fell by 0.73% on the same day. The stock also lagged its sector by 2.44%, trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning underscores the prevailing bearish sentiment among market participants.
Over multiple time horizons, Rossari Biotech’s returns have been notably negative. The stock has declined by 5.60% over the past week and 9.24% in the last month, compared to the Sensex’s respective declines of 2.28% and 4.96%. The three-month performance shows a sharper fall of 21.71%, while the Sensex dropped 7.32% in the same period.
Longer-term figures reveal a more pronounced underperformance. Over the last year, Rossari Biotech’s share price has fallen by 29.80%, contrasting with a 6.85% gain in the Sensex. Year-to-date, the stock is down 18.89% versus the Sensex’s 6.79% decline. The three-year and five-year returns further highlight the disparity, with Rossari Biotech down 23.91% and 53.47% respectively, while the Sensex gained 31.90% and 57.59% over those periods. The ten-year performance remains flat at 0.00%, starkly behind the Sensex’s 222.29% rise.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Financial Metrics and Valuation
Rossari Biotech’s recent financial indicators reveal areas of concern. The company’s operating profit to interest ratio for the quarter stands at a low 8.98 times, indicating tighter coverage of interest expenses. The return on capital employed (ROCE) for the half-year is at 12.97%, the lowest recorded, signalling reduced efficiency in generating returns from capital.
The debt-to-equity ratio for the half-year has increased to 0.28 times, the highest level observed, though the company’s average debt-to-equity ratio remains relatively low at 0.07 times. This suggests a modest increase in leverage but still within manageable limits compared to many peers.
Valuation metrics present a mixed picture. The company’s ROCE of 13.2% is accompanied by an enterprise value to capital employed ratio of 1.9, which is considered attractive. Despite this, the stock trades at a discount relative to its peers’ historical valuations. Over the past year, profits have inched up by 1.2%, yet the price-to-earnings growth (PEG) ratio is elevated at 16.7, reflecting a disconnect between earnings growth and market valuation.
Market Sentiment and Ratings
Rossari Biotech’s Mojo Score currently stands at 36.0, with a Mojo Grade of Sell, downgraded from Hold on 8 Dec 2025. The market capitalisation grade is rated at 3, indicating a smaller market cap relative to larger peers. These ratings reflect the stock’s ongoing underperformance and the challenges it faces in regaining investor confidence.
Institutional investors hold a significant 20.59% stake in the company, suggesting that entities with greater analytical resources maintain exposure despite the stock’s recent declines. This level of institutional holding may provide some stability amid volatile trading conditions.
Considering Rossari Biotech Ltd? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Comparative Performance and Sector Positioning
Within the specialty chemicals sector, Rossari Biotech’s performance has been consistently below par. The stock has underperformed the BSE500 index in each of the last three annual periods, highlighting persistent challenges in matching broader market and sector returns. This trend is evident in the stock’s negative returns over one, three, and five-year periods, contrasting sharply with the positive gains recorded by benchmark indices.
Despite the subdued price performance, the company’s fundamentals show some resilience. The low average debt-to-equity ratio and modest profit growth over the past year indicate a degree of financial stability. However, the elevated PEG ratio and declining operating profit coverage ratio suggest that the market is pricing in ongoing risks and uncertainties.
Rossari Biotech’s current valuation discount relative to peers may reflect the market’s cautious stance, given the stock’s recent price action and financial metrics. The company’s position below all major moving averages further emphasises the prevailing downward momentum.
Summary of Key Metrics
• All-time low price: Rs.471.6 (6 Mar 2026)
• Day change: -1.50%
• 1-year return: -29.80% vs Sensex +6.85%
• 3-year return: -23.91% vs Sensex +31.90%
• 5-year return: -53.47% vs Sensex +57.59%
• ROCE (HY): 12.97% (lowest)
• Operating profit to interest (Q): 8.98 times (lowest)
• Debt-to-equity (HY): 0.28 times (highest)
• Mojo Score: 36.0 (Sell, downgraded from Hold on 8 Dec 2025)
• Institutional holdings: 20.59%
Rossari Biotech Ltd’s recent price decline to an all-time low encapsulates a period of sustained underperformance relative to both sector peers and broader market indices. The company’s financial ratios and valuation metrics reflect a complex picture of modest profit growth amid increasing leverage and reduced capital efficiency. The stock’s technical indicators and rating downgrades further illustrate the challenges faced in reversing this trend.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
